Developer docs
API playgroundTry for free, no card

Search company profiles

Chiome Bioscience

Full company profile

uuid003pi6f

Namestring
Chiome Bioscience
Legal namestring
株式会社カイオム・바이오サイエンス
Websiteurl
chiome.co.jp
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Chiome Bioscience Inc. is a Tokyo-based clinical-stage biotechnology company (TSE Growth Market, ticker 4583; founded February 2005) that discovers and develops therapeutic antibody candidates and out-licenses them to pharmaceutical companies for clinical and commercial progression. Its proprietary ADLib® platform generates monoclonal antibodies in vitro using DT40 chicken B cells activated by Trichostatin A, enabling antigen-specific clone selection in approximately 10 days without animal immunization. The company has extended this core into a Human ADLib® system (genetically modified DT40 cells producing human antibodies directly, granted in Japan, Europe, and China) and the Tribody™ multi-specific antibody platform (acquired from Biotecnol Limited in December 2018), the latter yielding CBA-1535, the world's first trispecific antibody in clinical development. Supporting capabilities include ADLib® Affinity Maturation (KI-AMP), protein expression and purification, stable cell line development, and IgM purification, plus the ATAC® amatoxin-payload ADC technology introduced from Heidelberg Pharma in July 2022.

The clinical-stage pipeline includes CBA-1205 (ADCC-enhanced anti-DLK-1 antibody, Phase 1) and CBA-1535 (Tribody™ 5T4×CD3, Phase 1). Earlier-stage and out-licensed assets cover ADCT-701 (LIV-1205 ADC with PBD payload, Phase 1 via NCI/ADC Therapeutics, first patient dosed July 2024), PCDC (anti-CDCP1 ADC), PTRY (5T4×CD3×PD-L1 multi-specific), BMAA (anti-Semaphorin 3A), LIV-2008/2008b (anti-TROP-2, previously licensed to Shanghai Henlius until January 2023), PFKR (anti-CX3CR1, out-licensed to Asahi Kasei Pharma for SPMS), and PXLR (anti-CXCL1/2/3/5).

The company operates two business segments. The primary growth driver is Drug Discovery and Development, which generates upfront signing fees, development milestone payments (tied to IND filing and Phase transitions), and royalties on net sales from out-licensed candidates. The second segment is Drug Discovery Support Services, which provides antibody generation using ADLib®/hybridoma/B cell cloning, protein expression and purification, and stable cell line development on a fee-for-service, project-by-project basis to pharmaceutical companies, diagnostic companies, and academic/research institutions globally. Service revenue is reported as ¥210M (2018), ¥420M (2019), and ¥480M (2020), with continued growth since 2020; pricing is custom and not publicly disclosed. Distribution is direct, consultative, and technically-led, executed by PhD-qualified staff from initial inquiry through project delivery.

Short descriptiontext

Chiome Bioscience is a Tokyo-based clinical-stage biotechnology company that develops and out-licenses therapeutic antibody candidates using its proprietary ADLib® in vitro antibody platform, while offering antibody generation and protein engineering services to pharmaceutical, diagnostic, and research clients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShibuya, Japan
HQ citystring
Shibuya
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic antibody discovery, monoclonal antibody services, antibody drug development, biotech contract research, ADC development
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Therapeutic Antibody Discovery & Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Discovery and Development (Out-licensing)
TypeLicensing Royalties
Description

Chiome develops antibody drug candidates from basic/exploratory research through preclinical stage and out-licenses them to pharmaceutical companies. Revenue comes from upfront signing fees, development milestone payments tied to progress (e.g., IND filing, Phase transitions), and royalty payments on net sales if the product reaches market. This is the primary growth driver.

chiome.co.jp
2Drug Discovery Support Services (Contract/Fee-for-service)
TypeProfessional Services
Description

Chiome provides antibody generation services (using ADLib® system, hybridoma, B cell cloning) and recombinant protein preparation/purification services to pharmaceutical companies, diagnostic companies, and academic/research institutions on a fee-for-service basis. Services can be individual project-based, comprehensive contracts, or collaborative research agreements. Revenue from this segment has been growing (from ¥210M in 2018 to ¥480M in 2020).

chiome.co.jp
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom project-based antibody generation services
ModelOtherBilling cadenceOther
Notes

ADLib® mAb generation service: ELISA screening results reported in approximately 3 weeks; candidate clone antibody sequence information delivered approximately 2 weeks thereafter. ADLib® Affinity Maturation (KI-AMP): vector construction to cell line QC in approximately 8 weeks, followed by affinity maturation for approximately 1.5 months. Pricing determined per project based on customer needs.

chiome.co.jp
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1ADLib® System
Description

Proprietary monoclonal antibody generation technology using DT40 chicken B cells for rapid in vitro antibody discovery without animal immunization.

chiome.co.jp
+3 more records
Core offering1 text field

Chiome Bioscience operates two integrated business segments: (1) Drug Discovery and Development — proprietary antibody drug candidates (including CBA-1205, CBA-1535, PCDC, and others) developed from basic research through preclinical stage and out-licensed to pharmaceutical companies for upfront fees, milestones, and royalties; and (2) Drug Discovery Support Services — fee-for-service antibody generation using the proprietary ADLib® system, hybridoma, and B cell cloning, plus recombinant protein expression/purification and stable cell line development for pharmaceutical companies, diagnostic firms, and academic research institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CBA-1205 Phase 1 first-in-human trial (AACR 2023): No dose-limiting toxicities or Grade 3+ serious adverse events across 7 cohorts (0.1–30mg/kg). 8 of 22 patients showed stable disease (SD). Long-term SD in melanoma (80 weeks), thymoma (39 weeks), pancreatic cancer (41 weeks). Partial response (PR) confirmed in 1 patient.
+3 more records
Product overview1 text field

Chiome Bioscience operates two main business segments: (1) Drug Discovery and Development Business - developing therapeutic antibody candidates for out-licensing to pharmaceutical companies, with pipeline products including CBA-1205 (Phase 1, anti-DLK-1 for liver/lung cancer), CBA-1535 (Phase 1, Tribody™ trispecific for solid tumors), PCDC (ADC candidate, anti-CDCP1), and other pipeline candidates targeting TROP-2, Semaphorin3A, and CX3CR1; and (2) Drug Discovery Support Business - providing contract services including antibody generation using the proprietary ADLib® system, protein expression/purification, and stable cell line development to pharmaceutical companies, diagnostic companies, and research institutions. The company's core technology is the ADLib® system, a monoclonal antibody generation platform that does not require animal immunization.

Product and service12 records
1CBA-1205 (ADCC enhanced anti-DLK-1 antibody)
CategoryTherapeutic antibody (in-house pipeline, Phase 1)
Description

ADCC-enhanced humanized anti-DLK-1 monoclonal antibody for cancer treatment; first-in-class therapeutic antibody targeting hepatocellular carcinoma, lung cancer, and neuroblastoma; currently in Phase 1 clinical trial in Japan.

2CBA-1535 (Tribody™ anti-5T4×CD3)
CategoryTherapeutic antibody (in-house pipeline, Phase 1)
Description

Humanized trispecific anti-5T4×CD3 antibody (Tribody™) for cancer treatment; world's first Tribody™ format in clinical trials targeting malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC.

3PCDC (anti-CDCP1 antibody ADC candidate)
CategoryTherapeutic antibody ADC (preclinical pipeline)
Description

Humanized anti-CDCP1 monoclonal antibody being developed as an antibody-drug conjugate with amatoxin payload (ATAC®); first-in-class therapeutic target for solid tumors including lung, colorectal, pancreatic, breast, and ovarian cancers; available for licensing.

4PTRY (5T4×CD3×PD-L1 Tribody™)
CategoryTherapeutic antibody (preclinical pipeline)
Description

Humanized multi-specific antibody using Tribody™ technology recognizing three molecules (5T4×CD3×PD-L1) for cancer immunotherapy targeting malignant mesothelioma, lung cancer, and TNBC; preclinical pipeline candidate with patent application.

5BMAA (anti-Semaphorin 3A antibody)
CategoryTherapeutic antibody (preclinical pipeline)
Description

Humanized anti-Semaphorin 3A antibody developed using ADLib® system for renal and other diseases; collaboration with Yokohama City University; available for licensing.

6LIV-2008/2008b (anti-TROP-2 antibody)
CategoryTherapeutic antibody (preclinical pipeline)
Description

Humanized anti-TROP-2 monoclonal antibody for cancer treatment; best-in-class therapeutic antibody targeting breast cancer (TNBC), lung cancer, and colorectal cancer; available for licensing.

7PFKR (anti-CX3CR1 antibody)
CategoryTherapeutic antibody (out-licensed)
Description

Humanized anti-CX3CR1 antibody for autoimmune neurological diseases; functional inhibitory antibody targeting the Fractalkine (CX3CL1) receptor for secondary progressive multiple sclerosis (SPMS); licensed to Asahi Kasei Pharma.

8PXLR (anti-CXCL1/2/3/5 antibody)
CategoryTherapeutic antibody (preclinical pipeline)
Description

Humanized antibody targeting CXCL1/2/3/5 chemokines for cancer treatment; improves drug-resistant cancer microenvironment by reducing immunosuppressor cells in solid tumors; available for licensing.

9ADCT-701 (LIV-1205 ADC)
CategoryTherapeutic antibody ADC (out-licensed, Phase 1)
Description

Antibody-drug conjugate of Chiome's LIV-1205 anti-DLK-1 antibody with PBD (pyrrolobenzodiazepine) payload, targeting DLK-1 for solid tumors including neuroendocrine tumors; Phase 1 conducted by the National Cancer Institute (NCI) under license to ADC Therapeutics SA.

10ADLib® System Antibody Generation Services
CategoryDrug discovery support service
Description

Monoclonal antibody generation services using the proprietary ADLib® system, including antigen-specific antibody generation and affinity maturation (KI-AMP); supports therapeutic antibodies, in vitro diagnostics, and life science research for pharmaceutical companies, diagnostic companies, and research institutions.

11Protein Expression and Purification Service
CategoryDrug discovery support service
Description

Recombinant protein (antigen) expression and purification services including endotoxin-free plasmid isolation, transient mammalian cell expression, customizable purification, and protein analytics including membrane proteins.

12Stable Cell Line Development Service
CategoryDrug discovery support service
Description

Stable cell line generation services for recombinant protein and antibody production using recombinant DNA technology for efficient expression.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Heidelberg Pharma AG
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2022-07-01
Description

Chiome introduced the ATAC®Platform technology from Heidelberg Pharma AG (Germany) for use with PCDC (anti-CDCP1 antibody ADC). The technology uses amatoxin (mushroom-derived toxin) as a cytotoxic payload, enabling enhanced cell-killing potency. The technology was applied to PCDC ADC for solid tumors (lung, colorectal, pancreatic, breast, ovarian).

chiome.co.jp
2Shanghai Henlius Biotech
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Chiome executed a license agreement with Shanghai Henlius Biotech (China) for the development, manufacture, and commercialization of anti-TROP-2 antibodies LIV-2008/2008b in China. The license agreement ended in January 2023.

chiome.co.jp
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-12-01
Description

Chiome executed an Asset Purchase Agreement to acquire Tb535H (now CBA-1535), a tri-specific (Tribody™) cancer therapeutic antibody, and the Tribody™ multispecific antibody technology platform. This acquisition provided Chiome with its second clinical-stage asset and a platform for generating additional multi-specific antibody candidates.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-09-01
Description

Chiome executed a license agreement with ADC Therapeutics SA (Switzerland) for the development, manufacture, and commercialization of an ADC of LIV-1205 (the company's anti-DLK-1 antibody). Development code assigned is ADCT-701. NCI filed IND in the US, and first patient dosing for neuroendocrine tumors began in July 2024.

5RIKEN (理化学研究所)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2005-07-01
Description

Chiome obtained an exclusive license from RIKEN and the Japan Science and Technology Agency (JST) to commercialize the ADLib® system platform technology, with sublicensing rights to third parties. In 2010, Chiome concluded a payment-based technology transfer agreement with JST for the ADLib® system patent. The technology was originally developed by Dr. Kunihiro Ohta at RIKEN.

chiome.co.jp
Strategic tierMajorTypeTechnology or Integration
Description

ProBioGen AG (Germany, Berlin) co-developed the manufacturing process for CBA-1205 clinical drug substance with Chiome. The collaboration included application of ProBioGen's GlymaxX® glycan modification technology for ADCC enhancement. CBA-1205 is manufactured using a standard monoclonal antibody process (cell culture, purification, formulation) with a proprietary hydrophobic interaction chromatography step.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NCI (USA) completed IND submission in the US for ADCT-701 (LIV-1205 ADC), and the first patient dosing for neuroendocrine tumors (Phase 1) started in July 2024. ADCT-701 is an ADC combining Chiome's LIV-1205 anti-DLK-1 antibody with PBD (pyrrolobenzodiazepine) payload.

8The University of Tokyo
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Joint research with the University of Tokyo to scientifically validate and evaluate the practical utility of the Human ADLib® system. Results of this collaboration were published in Cellular & Molecular Immunology in 2020, demonstrating the system's utility for antibody drug discovery.

chiome.co.jp
9National Center of Neurology and Psychiatry (NCNP)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

NCNP collaborated with Chiome on the development of PFKR (humanized anti-CX3CR1 antibody) for the treatment of secondary progressive multiple sclerosis (SPMS) and other autoimmune neurological diseases. PFKR has been out-licensed to Asahi Kasei Pharma.

chiome.co.jp
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Through joint research with Professor Yoshio Goshima at Yokohama City University, Chiome established BMAA — a humanized anti-Semaphorin 3A antibody demonstrating both selectivity and functional inhibitory activity. Research published in Scientific Reports (2019) showed the antibody promotes nerve regeneration in early-stage peripheral nerve injury models.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Osaka Metropolitan University collaborated with Chiome on the development of PXLR (humanized anti-CXCL1/2/3/5 antibody) for the improvement of drug-resistant cancer microenvironments in solid tumors.

12Ceinge-Biotecnologie Avanzate (Italy)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Chiome collaborated with Ceinge (Naples, Italy) on cancer immunotherapy research using Tribody™ technology. Joint research generated data on tribody constructs combining 5T4×CD3 with immune checkpoint molecules (PD-1, LAG-3, PD-L1), published in Journal of Experimental & Clinical Cancer Research in 2022.

chiome.co.jp
13Niigata University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Niigata University published research in Scientific Reports (2019) on the role of Semaphorin 3A in early-stage peripheral nerve regeneration using Chiome's anti-Semaphorin 3A antibody, demonstrating that antibody-mediated inhibition of SEMA3A promoted nerve regeneration at the site of injury.

chiome.co.jp
14Asahi Kasei Pharma
Strategic tierCoreTypeTechnology or Integration
Description

PFKR (humanized anti-CX3CR1 antibody) has been out-licensed to Asahi Kasei Pharma for the treatment of autoimmune neurological diseases including secondary progressive multiple sclerosis (SPMS). PFKR is a functional inhibitory antibody targeting the Fractalkine (CX3CL1) receptor.

chiome.co.jp
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chiome Bioscience

Therapeutic Antibody Discovery & Developmentchiome.co.jp

Chiome Bioscience is a Tokyo-based clinical-stage biotechnology company that develops and out-licenses therapeutic antibody candidates using its proprietary ADLib® in vitro antibody platform, while offering antibody generation and protein engineering services to pharmaceutical, diagnostic, and research clients globally.

What Chiome Bioscience does

Chiome Bioscience Inc. is a Tokyo-based clinical-stage biotechnology company (TSE Growth Market, ticker 4583; founded February 2005) that discovers and develops therapeutic antibody candidates and out-licenses them to pharmaceutical companies for clinical and commercial progression. Its proprietary ADLib® platform generates monoclonal antibodies in vitro using DT40 chicken B cells activated by Trichostatin A, enabling antigen-specific clone selection in approximately 10 days without animal immunization. The company has extended this core into a Human ADLib® system (genetically modified DT40 cells producing human antibodies directly, granted in Japan, Europe, and China) and the Tribody™ multi-specific antibody platform (acquired from Biotecnol Limited in December 2018), the latter yielding CBA-1535, the world's first trispecific antibody in clinical development. Supporting capabilities include ADLib® Affinity Maturation (KI-AMP), protein expression and purification, stable cell line development, and IgM purification, plus the ATAC® amatoxin-payload ADC technology introduced from Heidelberg Pharma in July 2022.

The clinical-stage pipeline includes CBA-1205 (ADCC-enhanced anti-DLK-1 antibody, Phase 1) and CBA-1535 (Tribody™ 5T4×CD3, Phase 1). Earlier-stage and out-licensed assets cover ADCT-701 (LIV-1205 ADC with PBD payload, Phase 1 via NCI/ADC Therapeutics, first patient dosed July 2024), PCDC (anti-CDCP1 ADC), PTRY (5T4×CD3×PD-L1 multi-specific), BMAA (anti-Semaphorin 3A), LIV-2008/2008b (anti-TROP-2, previously licensed to Shanghai Henlius until January 2023), PFKR (anti-CX3CR1, out-licensed to Asahi Kasei Pharma for SPMS), and PXLR (anti-CXCL1/2/3/5).

The company operates two business segments. The primary growth driver is Drug Discovery and Development, which generates upfront signing fees, development milestone payments (tied to IND filing and Phase transitions), and royalties on net sales from out-licensed candidates. The second segment is Drug Discovery Support Services, which provides antibody generation using ADLib®/hybridoma/B cell cloning, protein expression and purification, and stable cell line development on a fee-for-service, project-by-project basis to pharmaceutical companies, diagnostic companies, and academic/research institutions globally. Service revenue is reported as ¥210M (2018), ¥420M (2019), and ¥480M (2020), with continued growth since 2020; pricing is custom and not publicly disclosed. Distribution is direct, consultative, and technically-led, executed by PhD-qualified staff from initial inquiry through project delivery.

Chiome Bioscience firmographics

Firmographics
Name
Chiome Bioscience
Legal name
株式会社カイオム・바이오サイエンス
Website
https://chiome.co.jp
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Chiome Bioscience is a Tokyo-based clinical-stage biotechnology company that develops and out-licenses therapeutic antibody candidates using its proprietary ADLib® in vitro antibody platform, while offering antibody generation and protein engineering services to pharmaceutical, diagnostic, and research clients globally.
Ownership category
akta.pro rank

Chiome Bioscience industry classification

Industry
Product category
Therapeutic Antibody Discovery & Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Therapeutic antibody discovery
  • Monoclonal antibody services
  • Antibody drug development
  • Biotech contract research
  • ADC development

Where Chiome Bioscience is headquartered

Location

Headquarters

HQ city
Shibuya
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

Chiome Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Discovery and Development (Out-licensing): Chiome develops antibody drug candidates from basic/exploratory research through preclinical stage and out-licenses them to pharmaceutical companies. Revenue comes from upfront signing fees, development milestone payments tied to progress (e.g., IND filing, Phase transitions), and royalty payments on net sales if the product reaches market. This is the primary growth driver.
  2. Drug Discovery Support Services (Contract/Fee-for-service): Chiome provides antibody generation services (using ADLib® system, hybridoma, B cell cloning) and recombinant protein preparation/purification services to pharmaceutical companies, diagnostic companies, and academic/research institutions on a fee-for-service basis. Services can be individual project-based, comprehensive contracts, or collaborative research agreements. Revenue from this segment has been growing (from ¥210M in 2018 to ¥480M in 2020).

Pricing tiers

ModelBillingPrice
OtherOtherCustom project-based antibody generation services

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Chiome Bioscience product offering

Product offering

Core offering

Chiome Bioscience operates two integrated business segments: (1) Drug Discovery and Development — proprietary antibody drug candidates (including CBA-1205, CBA-1535, PCDC, and others) developed from basic research through preclinical stage and out-licensed to pharmaceutical companies for upfront fees, milestones, and royalties; and (2) Drug Discovery Support Services — fee-for-service antibody generation using the proprietary ADLib® system, hybridoma, and B cell cloning, plus recombinant protein expression/purification and stable cell line development for pharmaceutical companies, diagnostic firms, and academic research institutions.

Product overview

Chiome Bioscience operates two main business segments: (1) Drug Discovery and Development Business - developing therapeutic antibody candidates for out-licensing to pharmaceutical companies, with pipeline products including CBA-1205 (Phase 1, anti-DLK-1 for liver/lung cancer), CBA-1535 (Phase 1, Tribody™ trispecific for solid tumors), PCDC (ADC candidate, anti-CDCP1), and other pipeline candidates targeting TROP-2, Semaphorin3A, and CX3CR1; and (2) Drug Discovery Support Business - providing contract services including antibody generation using the proprietary ADLib® system, protein expression/purification, and stable cell line development to pharmaceutical companies, diagnostic companies, and research institutions. The company's core technology is the ADLib® system, a monoclonal antibody generation platform that does not require animal immunization.

Differentiator

Problem solved

Functional benefit

Brands

  • ADLib® System: Proprietary monoclonal antibody generation technology using DT40 chicken B cells for rapid in vitro antibody discovery without animal immunization.
  • Human ADLib® System
  • Tribody™
  • ADLib® Affinity Maturation (KI-AMP)

Products and services

  • CBA-1205 (ADCC enhanced anti-DLK-1 antibody) ADCC-enhanced humanized anti-DLK-1 monoclonal antibody for cancer treatment; first-in-class therapeutic antibody targeting hepatocellular carcinoma, lung cancer, and neuroblastoma; currently in Phase 1 clinical trial in Japan.
  • CBA-1535 (Tribody™ anti-5T4×CD3) Humanized trispecific anti-5T4×CD3 antibody (Tribody™) for cancer treatment; world's first Tribody™ format in clinical trials targeting malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC.
  • PCDC (anti-CDCP1 antibody ADC candidate) Humanized anti-CDCP1 monoclonal antibody being developed as an antibody-drug conjugate with amatoxin payload (ATAC®); first-in-class therapeutic target for solid tumors including lung, colorectal, pancreatic, breast, and ovarian cancers; available for licensing.
  • PTRY (5T4×CD3×PD-L1 Tribody™) Humanized multi-specific antibody using Tribody™ technology recognizing three molecules (5T4×CD3×PD-L1) for cancer immunotherapy targeting malignant mesothelioma, lung cancer, and TNBC; preclinical pipeline candidate with patent application.
  • BMAA (anti-Semaphorin 3A antibody) Humanized anti-Semaphorin 3A antibody developed using ADLib® system for renal and other diseases; collaboration with Yokohama City University; available for licensing.
  • LIV-2008/2008b (anti-TROP-2 antibody) Humanized anti-TROP-2 monoclonal antibody for cancer treatment; best-in-class therapeutic antibody targeting breast cancer (TNBC), lung cancer, and colorectal cancer; available for licensing.
  • PFKR (anti-CX3CR1 antibody) Humanized anti-CX3CR1 antibody for autoimmune neurological diseases; functional inhibitory antibody targeting the Fractalkine (CX3CL1) receptor for secondary progressive multiple sclerosis (SPMS); licensed to Asahi Kasei Pharma.
  • PXLR (anti-CXCL1/2/3/5 antibody) Humanized antibody targeting CXCL1/2/3/5 chemokines for cancer treatment; improves drug-resistant cancer microenvironment by reducing immunosuppressor cells in solid tumors; available for licensing.
  • ADCT-701 (LIV-1205 ADC) Antibody-drug conjugate of Chiome's LIV-1205 anti-DLK-1 antibody with PBD (pyrrolobenzodiazepine) payload, targeting DLK-1 for solid tumors including neuroendocrine tumors; Phase 1 conducted by the National Cancer Institute (NCI) under license to ADC Therapeutics SA.
  • ADLib® System Antibody Generation Services Monoclonal antibody generation services using the proprietary ADLib® system, including antigen-specific antibody generation and affinity maturation (KI-AMP); supports therapeutic antibodies, in vitro diagnostics, and life science research for pharmaceutical companies, diagnostic companies, and research institutions.
  • Protein Expression and Purification Service Recombinant protein (antigen) expression and purification services including endotoxin-free plasmid isolation, transient mammalian cell expression, customizable purification, and protein analytics including membrane proteins.
  • Stable Cell Line Development Service Stable cell line generation services for recombinant protein and antibody production using recombinant DNA technology for efficient expression.

Quantifiable outcome

  • CBA-1205 Phase 1 first-in-human trial (AACR 2023): No dose-limiting toxicities or Grade 3+ serious adverse events across 7 cohorts (0.1–30mg/kg). 8 of 22 patients showed stable disease (SD). Long-term SD in melanoma (80 weeks), thymoma (39 weeks), pancreatic cancer (41 weeks). Partial response (PR) confirmed in 1 patient.
  • +3 more outcomes

Companies that use Chiome Bioscience

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Chiome Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Chiome Bioscience partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered major, core and minor.

  • Heidelberg Pharma AGmajorTechnology or Integration · 1 July 2022Chiome introduced the ATAC®Platform technology from Heidelberg Pharma AG (Germany) for use with PCDC (anti-CDCP1 antibody ADC). The technology uses amatoxin (mushroom-derived toxin) as a cytotoxic payload, enabling enhanced cell-killing potency. The technology was applied to PCDC ADC for solid tumors (lung, colorectal, pancreatic, breast, ovarian).
  • Shanghai Henlius BiotechmajorTechnology or Integration · 1 January 2021Chiome executed a license agreement with Shanghai Henlius Biotech (China) for the development, manufacture, and commercialization of anti-TROP-2 antibodies LIV-2008/2008b in China. The license agreement ended in January 2023.
  • Biotecnol LimitedcoreTechnology or Integration · 1 December 2018Chiome executed an Asset Purchase Agreement to acquire Tb535H (now CBA-1535), a tri-specific (Tribody™) cancer therapeutic antibody, and the Tribody™ multispecific antibody technology platform. This acquisition provided Chiome with its second clinical-stage asset and a platform for generating additional multi-specific antibody candidates.
  • ADC Therapeutics SAcoreTechnology or Integration · 1 September 2017Chiome executed a license agreement with ADC Therapeutics SA (Switzerland) for the development, manufacture, and commercialization of an ADC of LIV-1205 (the company's anti-DLK-1 antibody). Development code assigned is ADCT-701. NCI filed IND in the US, and first patient dosing for neuroendocrine tumors began in July 2024.
  • RIKEN (理化学研究所)coreTechnology or Integration · 1 July 2005Chiome obtained an exclusive license from RIKEN and the Japan Science and Technology Agency (JST) to commercialize the ADLib® system platform technology, with sublicensing rights to third parties. In 2010, Chiome concluded a payment-based technology transfer agreement with JST for the ADLib® system patent. The technology was originally developed by Dr. Kunihiro Ohta at RIKEN.
  • ProBioGen AGmajorTechnology or IntegrationProBioGen AG (Germany, Berlin) co-developed the manufacturing process for CBA-1205 clinical drug substance with Chiome. The collaboration included application of ProBioGen's GlymaxX® glycan modification technology for ADCC enhancement. CBA-1205 is manufactured using a standard monoclonal antibody process (cell culture, purification, formulation) with a proprietary hydrophobic interaction chromatography step.
  • National Cancer Institute (NCI)coreStrategic or Co-development PartnerNCI (USA) completed IND submission in the US for ADCT-701 (LIV-1205 ADC), and the first patient dosing for neuroendocrine tumors (Phase 1) started in July 2024. ADCT-701 is an ADC combining Chiome's LIV-1205 anti-DLK-1 antibody with PBD (pyrrolobenzodiazepine) payload.
  • The University of TokyomajorStrategic or Co-development PartnerJoint research with the University of Tokyo to scientifically validate and evaluate the practical utility of the Human ADLib® system. Results of this collaboration were published in Cellular & Molecular Immunology in 2020, demonstrating the system's utility for antibody drug discovery.
  • National Center of Neurology and Psychiatry (NCNP)majorStrategic or Co-development PartnerNCNP collaborated with Chiome on the development of PFKR (humanized anti-CX3CR1 antibody) for the treatment of secondary progressive multiple sclerosis (SPMS) and other autoimmune neurological diseases. PFKR has been out-licensed to Asahi Kasei Pharma.
  • Yokohama City University (Professor Yoshio Goshima)majorStrategic or Co-development PartnerThrough joint research with Professor Yoshio Goshima at Yokohama City University, Chiome established BMAA — a humanized anti-Semaphorin 3A antibody demonstrating both selectivity and functional inhibitory activity. Research published in Scientific Reports (2019) showed the antibody promotes nerve regeneration in early-stage peripheral nerve injury models.
  • Osaka Metropolitan UniversityminorStrategic or Co-development PartnerOsaka Metropolitan University collaborated with Chiome on the development of PXLR (humanized anti-CXCL1/2/3/5 antibody) for the improvement of drug-resistant cancer microenvironments in solid tumors.
  • Ceinge-Biotecnologie Avanzate (Italy)majorStrategic or Co-development PartnerChiome collaborated with Ceinge (Naples, Italy) on cancer immunotherapy research using Tribody™ technology. Joint research generated data on tribody constructs combining 5T4×CD3 with immune checkpoint molecules (PD-1, LAG-3, PD-L1), published in Journal of Experimental & Clinical Cancer Research in 2022.
  • Niigata UniversityminorStrategic or Co-development PartnerNiigata University published research in Scientific Reports (2019) on the role of Semaphorin 3A in early-stage peripheral nerve regeneration using Chiome's anti-Semaphorin 3A antibody, demonstrating that antibody-mediated inhibition of SEMA3A promoted nerve regeneration at the site of injury.
  • Asahi Kasei PharmacoreTechnology or IntegrationPFKR (humanized anti-CX3CR1 antibody) has been out-licensed to Asahi Kasei Pharma for the treatment of autoimmune neurological diseases including secondary progressive multiple sclerosis (SPMS). PFKR is a functional inhibitory antibody targeting the Fractalkine (CX3CL1) receptor.

Scale indicators4 records

Recent moves10 records

Expansion highlights6 records

Chiome Bioscience competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Chiome Bioscience social profiles

Digital presence

Chiome Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chiome Bioscience leadership team

Management profile

Number of profiles

Profiles7 records

Chiome Bioscience funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chiome Bioscience M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chiome Bioscience

What does Chiome Bioscience do?

Chiome Bioscience operates two integrated business segments: (1) Drug Discovery and Development — proprietary antibody drug candidates (including CBA-1205, CBA-1535, PCDC, and others) developed from basic research through preclinical stage and out-licensed to pharmaceutical companies for upfront fees, milestones, and royalties; and (2) Drug Discovery Support Services — fee-for-service antibody generation using the proprietary ADLib® system, hybridoma, and B cell cloning, plus recombinant protein expression/purification and stable cell line development for pharmaceutical companies, diagnostic firms, and academic research institutions.

Is Chiome Bioscience a public or private company?

Chiome Bioscience is a public company. It is classified as public and is currently operating.

When was Chiome Bioscience founded?

Chiome Bioscience was founded in 2005. It employs 11 to 50 people.

Where is Chiome Bioscience based?

Chiome Bioscience is headquartered in Shibuya, Japan, in the Asia region.

How does Chiome Bioscience make money?

Two revenue lines are on record. Drug Discovery and Development (Out-licensing) is the primary driver. The others are drug Discovery Support Services (Contract/Fee-for-service).

Does Chiome Bioscience have an API?

No public API is recorded for Chiome Bioscience.

What industry is Chiome Bioscience in?

Chiome Bioscience's product category is Therapeutic Antibody Discovery & Development. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals